We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney

Sara M. Tolaney MD, MPH

Associate Director, Susan F. Smith Center for Women’s Cancers; Director of Clinical Trials, Breast Oncology; Director of Breast Immunotherapy Clinical Research; Senior Physician, Dana-Farber Cancer Institute, Boston, Massachusetts; Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. 

In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on the development of novel therapies in the treatment of breast cancer.

Disclosures

Dr. Tolaney reports the following disclosures: Institutional research funding from Genentech, Eli Lilly, Pfizer, Novartis, Exelixis, Eisai, Bristol Meyers Squibb, Merck, Nanostring, AstraZeneca, Nektar, and Cyclacel.  Advisory services provided to Genentech, Eli Lilly, Pfizer, Novartis, Eisai, Merck, Nanostring, AstraZeneca, Nektar and Puma.

Conflict of Interests: All Research Support goes to Institution

  • AstraZeneca, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Lilly, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Merck, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Nektar, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Novartis, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Pfizer, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Genentech/Roche, PI of Study(s); Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Immunomedics , PI of Study(s); Advisory Board, Institutional Research Funds; Honorarium; travel expense reimbursement, Breast Cancer Research
  • Exelixis PI of Study(s), Institutional Research Funds, Breast Cancer Research
  • Bristol-Myers Squibb, PI of Study(s) Consultant; Advisory Board, Institutional Research Funds; honorarium;Breast Cancer Research
  • Eisai, PI of Study(s); Consultant; Advisory Board  Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Nanostring, PI of Study(s); Consultant; Advisory Board, Institutional Research Funds; honorarium; travel expense reimbursement, Breast Cancer Research
  • Puma, Advisory Board, Honorarium; travel expense reimbursement, Breast Cancer Research
  • Cyclacel, PI of Study(s); Institutional Research Funds, Breast Cancer Research
  • Sanofi, Advisory Board, Honorarium, Breast Cancer Research
  • Celldex, Advisory Board Honorarium; travel expense reimbursement, Breast Cancer Research
  • Paxman, Advisory Board/Consultant, Honorarium, Breast Cancer Research
  • Seattle Genetics, Steering Committee, Honorarium, Breast Cancer Research
  • Odonate –PI of study(s), Institutional research funds; Consulting/Advisory Board, honorarium – Breast Cancer Research
  • Seattle Genetics -- PI of study(s), Institutional research funds; Steering Committee/Advisory Board, honorarium – Breast Cancer Research
  • Silverback Therapeutics – Advisory Board, honorarium – Breast Cancer Research
  • G1 Therapeutics – Advisory Board, honorarium – Breast Cancer Research
  • Abbvie – Consulting, honorarium – Breast Cancer Research
  • Athenex – Consulting, honorarium – Breast Cancer Research
  • OncoPep – Advisory Board, honorarium – Breast Cancer Research
  • Daiichi-Sankyo – Advisory Board, honorarium – Breast Cancer Research
  • Kyowa Kirin Pharmaceuticals – Advisory Board, honorarium – Breast Cancer Research
  • Samsung Bioepsis inc. – Advisory Board, honorarium – Breast Cancer Research
  • CytomX – Steering Committee, honorarium – Breast Cancer Research

 

Recent Contributions to PracticeUpdate:

  1. Immunotherapy Combinations for Advanced HR+ Breast Cancer: State-of-the-Science and Future Directions
  2. Key Takeaways From ESMO: Adjuvant HR+ Breast Cancer
  3. Immunotherapy in Early Triple-Negative Breast Cancer: New Data and Future Directions
  4. New Quality-of-Life Data for Tucatinib in HER2+ Breast Cancer
  5. ESMO 2020: Recommendations From Dr. Sara Tolaney for Breast Cancer
  6. ASCO 2020: Abstract Recommendations From Dr. Sara Tolaney for Breast Cancer
  7. Fulvestrant + Capivasertib vs Placebo After Relapse or Progression on an Aromatase Inhibitor in Metastatic, ER+ Breast Cancer
  8. 2019 Top Stories in Oncology: First Approval of Immunotherapy in Breast Cancer
  9. Adjuvant T-DM1 for Stage I HER2+ Breast Cancer
  10. Patient Perspectives on T-DM1 vs Paclitaxel/Trastuzumab for HER2+ Early Breast Cancer

Most Read This Week

Recently Updated